• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-15D filed by Longevity Acquisition Corporation

    4/1/21 1:05:04 PM ET
    $LOAC
    Business Services
    Finance
    Get the next $LOAC alert in real time by email
    15-15D 1 tm2111567-2_1515d.htm 15-15D

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 15

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

     

      Commission File Number   333-226699
         

    LONGEVITY ACQUISITION CORPORATION

    (Exact name of registrant as specified in its charter)

     

    5th Floor, 9 Bond Court
    Leeds
    LS1 2JZ
    United Kingdom
    Tel: +44 (0) 113 895 0130

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Ordinary Shares, no par value

    Redeemable Warrants

    Rights

    Units

    (Title of each class of securities covered by this Form)

     

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

      Rule 12g-4(a)(1) x      
      Rule 12g-4(a)(2) o      
      Rule 12h-3(b)(1)(i) x      
      Rule 12h-3(b)(1)(ii) o      
      Rule 15d-6 o      
      Rule 15d-22(b) o      

     

    Approximate number of holders of record as of the certification or notice date: 1

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Longevity Acquisition Corporation has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

      Longevity Acquisition Corporation
         
    Date: April 1, 2021 By: /s/ Duncan Peyton
       

    Name: Duncan Peyton
    Title: Director

     

     

     

    Get the next $LOAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LOAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LOAC
    SEC Filings

    View All

    SEC Form EFFECT filed by Longevity Acquisition Corporation

    EFFECT - Longevity Acquisition Corp (0001743858) (Filer)

    4/7/21 12:15:42 AM ET
    $LOAC
    Business Services
    Finance

    SEC Form 15-15D filed by Longevity Acquisition Corporation

    15-15D - Longevity Acquisition Corp (0001743858) (Filer)

    4/1/21 1:05:04 PM ET
    $LOAC
    Business Services
    Finance

    SEC Form POS AM filed by Longevity Acquisition Corporation

    POS AM - Longevity Acquisition Corp (0001743858) (Filer)

    3/31/21 1:21:13 PM ET
    $LOAC
    Business Services
    Finance

    $LOAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    4D pharma Announces Completion of Merger With Longevity Acquisition Corporation

    LEEDS, England--(BUSINESS WIRE)--4D pharma plc (Nasdaq: LBPS; AIM: DDDD) ("4D pharma" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome - today announced completion of its merger (“the Merger”) with Longevity Acquisition Corporation ("Longevity")(Nasdaq: LOAC). 4D pharma American Depositary Shares (“ADSs”) are expected to begin trading today on the Nasdaq Global Market under the ticker symbol ‘LBPS.’ Warrants of Longevity assumed by 4D pharma in the Merger are currently expected to begin trading on Nasdaq under the ticker symbol ‘LBPSW’ tomorrow, Tuesday, March 23, 2021. Lo

    3/22/21 3:00:00 AM ET
    $LOAC
    Business Services
    Finance

    Longevity Acquisition Corporation Announces Results of Special Meeting of Shareholders

    NEW YORK, March 18, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today the results of its special meeting of shareholders, which was held on March 17, 2021. At the special meeting, shareholders of the Company approved the merger, including a certain agreement and plan of merger, dated as of October 21, 2020, by and among 4d pharma plc, the Company and Dolphin Merger Sub Limited, and the related agreements and transactions contemplated thereby. About LOAC LOAC is a blank check company, also commonly referred to as a Special Purpose Acquisition Company, or SPAC, formed for the purpose of

    3/18/21 8:00:00 AM ET
    $LOAC
    Business Services
    Finance

    4D Pharma to Present at Upcoming Investor Conferences in March

    LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that 4D management will present at three upcoming investor conferences: Chardan's Virtual 3rd Annual Microbiome Medicines Summit: Monday March 8, 2021 at 11:45 am ET (16:45 GMT). H.C. Wainwright Global Life Sciences Conference: Available on-demand starting Tuesday, March 9, 2021 at 7:00 am ET (12:00 GMT). Oppenheimer’s 31st Annual Healthcare Conference: Tuesday, March 16, 2021 at 8:40 am ET (12:40 GMT). About 4D pharma Founded in February 2014, 4D pharma is a w

    3/3/21 7:00:00 AM ET
    $LOAC
    Business Services
    Finance

    $LOAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - Longevity Acquisition Corp (0001743858) (Subject)

    2/16/21 3:16:03 PM ET
    $LOAC
    Business Services
    Finance

    SEC Form SC 13G/A filed

    SC 13G/A - Longevity Acquisition Corp (0001743858) (Subject)

    2/16/21 7:36:20 AM ET
    $LOAC
    Business Services
    Finance

    SEC Form SC 13G/A filed

    SC 13G/A - Longevity Acquisition Corp (0001743858) (Subject)

    2/12/21 4:21:17 PM ET
    $LOAC
    Business Services
    Finance

    $LOAC
    Leadership Updates

    Live Leadership Updates

    View All

    4D Pharma Appoints John Beck as Chief Financial Officer and Member of the Management Team

    LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Company’s management team, bringing over 30 years of experience in finance, including three previous positions as Chief Financial Officer of publicly traded life sciences companies. “John will be an important addition to 4D pharma’s management team at such a pivotal time, as the company prepares to close our SPAC merger and begin trading on NASDAQ. His deep experience and financial expert

    3/1/21 7:00:00 AM ET
    $LOAC
    Business Services
    Finance